D-甲硫氨酸(D-Methionine) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

+ [2]

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病消化系统疾病口颌疾病+ [2]

在研适应症-

非在研适应症

神经性听力损失粘膜炎头颈部鳞状细胞癌

原研机构

Molecular Therapeutics, Inc.

在研机构-

非在研机构

The Sidney Kimmel Comprehensive Cancer Center

Molecular Therapeutics, Inc.

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C5H11NO2S

InChIKeyFFEARJCKVFRZRR-SCSAIBSYSA-N

CAS号348-67-4

关联

2

项与 D-甲硫氨酸相关的临床试验

NCT02903355

/ Terminated临床3期IIT

Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)

This prospective study is a randomized, double-blind, placebo-controlled Phase 3 clinical trial of oral D-methionine (D-met) to reduce noise-induced hearing loss (NIHL) and tinnitus. The goal of the study is to develop a safe, oral pharmacological agent to augment physical hearing protectors for noise exposures that exceed the protective capabilities of ear plugs and/or muffs. The study population is a cohort of Drill Sergeant (DS) instructor trainees during and 22 days after their 11 day weapons training. The primary objective of this study is to determine the efficacy of D-met in preventing NIHL or reducing tinnitus secondary to a minimum of 500 rounds of M-16 weapons training occurring over an 11 day period.

开始日期2013-09-01

申办/合作机构

Southern Illinois University Carbondale

NCT00427102

/ Terminated临床1期IIT

A Phase 1 Study of Oral MRX-1024 in Combination With Standard Fractionation Radiation Therapy and High-Dose Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Following Surgical Resection

Rationale for Study
Oral mucositis is a major complication arising from contemporary chemoradiation treatment of patients with head and neck cancer.
No effective therapy exists to prevent this complication in this population. MRX-1024 is an investigational agent that has demonstrated in in vitro and in vivo experiments to have the potential to exert a protective effect in normal mucosa cells, without interfering with the intended antitumor effect of radiation.
A pilot Phase 1 study of MRX-1024 was conducted in India in patients with head and neck cancer receiving radiation alone or radiation in combination with cisplatin or carboplatin. MRX 1024 doses of 100 mgkg given orally twice a day, five days a week during radiation treatment cycles, were well tolerated and appeared to exert a protective effect against the development of severe mucositis.
Twice daily doses of MRX 1024 impose a certain level of inconvenience to the patient, to their clinic companion, and to the general work flow within radiation oncology clinics.
This study is designed to study the safety and pharmacokinetics of both single daily dose and twice daily dose regimens of oral MRX 1024 given in conjunction with daily radiation fractions and intermittent high-dose cisplatin to patients with high-risk for recurrence head and neck cancer following surgical resection. The study will also document the incidence and severity of oral mucositis that occurs following such therapy. The results will be instrumental in determining the regimen of MRX 1024 to use in subsequent definitive clinical trials.

开始日期2007-01-01

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

100 项与 D-甲硫氨酸相关的临床结果

登录后查看更多信息

100 项与 D-甲硫氨酸相关的转化医学

登录后查看更多信息

100 项与 D-甲硫氨酸相关的专利（医药）

登录后查看更多信息

1,846

项与 D-甲硫氨酸相关的文献（医药）

2025-04-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

A bifunctional coumarin-based CD probe for chiral analysis of amino acids in aqueous solution

Article

作者: Duan, Wenzeng ; Pu, Lin ; Han, Miao ; Huang, Xianqiang ; Huo, Yanmin ; Yu, Wenxue ; Li, Yu

Amino acids play important roles in human pathology and physiology and the qualitative and quantitative determination of chiral amino acids in humans and mammals also has important impacts on the life sciences. Therefore, the introduction of artificial probes to assess the concentrations and enantiomeric compositions [ee = ([D] - [L])/([D] + [L])] of amino acids in aqueous solution is necessary in understanding certain biological processes and diagnosing and treating diseases. Herein, a bifunctional achiral coumarin probe (Br-Coumarin) is reported to determine the absolute configuration, ee value, and concentration of 16 amino acids in THF/H₂O = 1/4 solution at micromolar concentrations. The effectiveness and practicability of the sensing methods are illustrated through the evaluation of various ee values and concentrations of Cys, Pro, and Phe samples with good accuracy. Besides, the reactions of the probe with various amino acids exhibit different colors under daylight or UV light (365 nm). Particularly, Br-Coumarin can be used to visually detect Cys, Lys, Arg, and Pro with high selectivity under both daylight and UV light (365 nm) and exhibits excellent selectivity and sensitivity for the fluorescent recognition of Cys.

2025-03-01·Small

Cross‐Referencing Multifluid Metabolic Profiles on Hollow Dodecahedral Nanocages for Enhanced Disease Status Identification

Article

作者: Chen, Lingli ; Shi, Fangying ; Sun, Nianrong ; Yao, Qunyan ; Deng, Chunhui ; Qiao, Yiming

AbstractThe development of matrices has shown great potential for fluid metabolic analysis in disease detection. However, single‐fluid metabolomic analysis has been recognized as insufficient to fully capture the complexities of diseases such as liver disease, which limits detection accuracy. To this end, the hollow dodecahedral nanocages‐based analytical tool is developed, featuring four‐high characteristics of speed, throughput, efficiency, and patient compliance, to enhance extraction of multifluid metabolic profiles. The cross‐referencing of these profiles among different liver diseases, including hepatocellular carcinoma (HCC), chronic liver disease (CLD), and healthy controls, enhances the diagnosis of liver diseases, particularly achieving near‐perfect discrimination for HCC with an AUC value of 0.990, significantly outperforming any single fluid analysis. Additionally, the dynamic changes in expression levels of the key biomarkers throughout disease progression are explored, providing insights into their temporal evolution, and highlighting their role in monitoring disease status. This work highlights that multifluid metabolic analysis can comprehensively and sensitively reflect the disease status, enabling precise identification of complex diseases and facilitating personalized treatment.

2025-03-01·European Journal of Medicinal Chemistry

Discovery of proteolytically stable monocyte locomotion inhibitory factor peptide through systematic structural optimization

Article

作者: Li, Xiang ; Hu, Honggang ; Gao, Yuan ; Ji, Yajing ; Shi, Yejiao ; Zhang, Yuefan

The identification of novel molecular candidates capable of treating osteoarthritis (OA) has significant clinical implications. Monocyte locomotion inhibitory factor peptide (MLIF) is a pentapeptide derived from Entamoeba histolytica. It has been found possesses selective anti-inflammatory effects both in vitro and in vivo. Nonetheless, like many peptide therapeutics, MLIF has relatively poor proteolytic stability and short half-life in vivo, hindering its effective clinical applicability. To overcome these limitations, structural optimizations are needed to enhance the stability of MLIF while preserving or even enhancing its anti-inflammatory activities. Herein, a series of MLIF derivatives were designed and synthesized based on diverse structural modifications including N-terminal modifications, _d-amino acid replacement, N-methylation, sulfhydryl modification, cyclization, and splicing strategy. Among all the MLIF derivatives, MLIF 30 with replacing _l-methionine (Met) with _D-Met and linking the polyethylene glycol (PEG) to cysteine (Cys) of MLIF displayed enhanced in vitro anti-inflammatory activities. Further in vivo experiment demonstrated MLIF 30 could reduce cartilage inflammation and attenuate cartilage damage more effectively in the collagenase induced osteoarthritis (CIOA) mice due to its improved serum stability compared to the linear MLIF. These findings laid foundation for the development of potent and stable anti-inflammatory peptide therapeutics and pushed the frontier of MLIF for clinical OA treatment.

100 项与 D-甲硫氨酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	D-甲硫氨酸	-	DB02893

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头颈部鳞状细胞癌	临床3期	-	The Sidney Kimmel Comprehensive Cancer Center	2007-01-01
神经性听力损失	临床3期	-	Molecular Therapeutics, Inc.	-
粘膜炎	临床3期	-	Molecular Therapeutics, Inc.	-
粘膜炎	临床3期	-	Molecular Therapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02903355 (CTgov)	临床3期	噪声性听力损失	351	Placebo (Placebo)	繭範廠獵築蓋鹹積觸繭(艱鹽廠鏇齋製餘鬱襯淵) = 鹹壓鏇範齋築觸網願鹽糧蓋齋廠醖鏇顧廠鹹觸 (醖膚窪膚遞衊憲鹽憲窪, 積壓憲範遞艱範鏇鏇壓 ~ 獵憲鑰製鏇鬱衊顧範淵) 更多	-	2022-06-28
				D-methionine (D-methionine, Oral Liquid Suspension)	繭範廠獵築蓋鹹積觸繭(艱鹽廠鏇齋製餘鬱襯淵) = 餘衊夢選壓醖鏇艱襯窪糧蓋齋廠醖鏇顧廠鹹觸 (醖膚窪膚遞衊憲鹽憲窪, 獵餘築膚繭顧鏇網製鏇 ~ 齋衊築選壓構醖鹹遞製) 更多